PFIZER INC Deferred Federal Income Tax Expense (Benefit)
PFIZER INC (PFE) reported Deferred Federal Income Tax Expense (Benefit) of -$1.83 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-26
- PFIZER INC deferred federal income tax expense (benefit) for fiscal 2025 was -$1.83B.
- PFIZER INC deferred federal income tax expense (benefit) for fiscal 2024 was -$1.91B.
- PFIZER INC deferred federal income tax expense (benefit) for fiscal 2023 was -$2.61B.
- PFIZER INC deferred federal income tax expense (benefit) for fiscal 2022 was -$3.27B.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$1.83B 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$1.91B 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$2.61B 10-K · filed 2026-02-26 | |
| 2022-12-31 | -$3.27B 10-K · filed 2025-02-27 | |
| 2021-12-31 | -$3.85B 10-K · filed 2024-02-22 | |
| 2020-12-31 | -$1.16B 10-K · filed 2023-02-23 | -$1.06B 10-K · filed 2021-02-25 |
| 2019-12-31 | $1.25B 10-K · filed 2022-02-24 | $1.26B 10-K · filed 2020-02-27 |
| 2018-12-31 | -$1.64B 10-K · filed 2021-02-25 | -$1.66B 10-K · filed 2019-02-28 |
| 2017-12-31 | -$2.06B 10-K · filed 2020-02-27 | -$25.96B 10-K · filed 2018-02-22 |
| 2016-12-31 | -$419.00M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $300.00M 10-K · filed 2018-02-22 | |
| 2014-12-31 | $725.00M 10-K · filed 2017-02-23 | |
| 2013-12-31 | $2.12B 10-K · filed 2016-02-29 | |
| 2012-12-31 | $869.00M 10-K · filed 2015-02-27 | |
| 2010-12-31 | $2.03B 10-K · filed 2011-02-28 | |
| 2009-12-31 | -$10.00B 10-K · filed 2011-02-28 | |
| 2008-12-31 | $106.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |